Compare Moderna, Inc. (MRNA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs SYSCO Corporation — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while SYSCO Corporation trades at $81.33 (market cap $38.63B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays a 2.72% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SYY | |
|---|---|---|
Market Cap | $23.60B | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $81.80 | $91.16 |
52-Week Low | $22.36 | $69.30 |
Enterprise Value | $19.70B | $52.11B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
SYY trades at $81.22, down 0.58% on the day, with a bullish technical signal supported by moving averages. The company reported mixed Q1 2026 earnings, missing EPS expectations of $0.945 with $0.94, but maintains strong revenue growth, reaching $81.37B in 2025. Analyst consensus is bullish with a $84.75 price target, and the upcoming Q4 2026 earnings report on August 4 is a key catalyst. Recent news highlights operational efficiency gains and AI integration, including a Newsweek AI Impact Award.
SYY presents a moderate buy opportunity with upside to the consensus target, supported by stable cash flow and dividend payments. Risks include thin net margins of 2.08% and elevated debt levels, with long-term debt at $11.51B. The stock's valuation is reasonable with a P/E of 22.44, but margin pressure and economic sensitivity in the food distribution sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
